Hubert Birner
General Partner @ TVM Capital
Munich, Germany
Hubert Birner is a Series A investor at TVM Capital in Munich focused on Medical and Health Care. Hubert Birner is the Chairman of the board of directors of leon nanodrugs. Hubert Birner attended the Harvard Business School.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Hubert Birner invests in
MedicalHealth CarePharmaceuticalBiotechnologySaaS
Stages Hubert Birner invests in
Series ASeries BSeries CSeries DFunding Round
Countries Hubert Birner invests in
GermanyUnited StatesThe Netherlands
Investment Focus
Industry
- Medical 3 (30%)
- Health Care 3 (30%)
- Pharmaceutical 3 (30%)
- Biotechnology 2 (20%)
- SaaS 1 (10%)
Stage
- Series A 2 (20%)
- Series B 2 (20%)
- Series C 2 (20%)
- Series D 2 (20%)
- Funding Round 1 (10%)
Country
- Germany 2 (20%)
- United States 1 (10%)
- The Netherlands 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series D / Aug 06, 2024 | |
Smart Reporting
|
Smart Reporting offers a digital health solution for structured medical reporting. Smart Reporting offers an intelligent software for physicians which improves quality and efficiency. The first platform was launched in radiology and supports radiologists in generating high-quality medical reports by applying guideline-compliant criteria in theirreports. | $24.5M / Series C / Apr 22, 2024 | |
|
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series B / Apr 16, 2020 | |
|
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series A / Jul 27, 2015 | |
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M / Series D / May 16, 2014 | |
|
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $15.2M / Series C / Aug 12, 2011 | |
|
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $50M / Series B / May 28, 2009 | |
SpePharm
|
SpePharm is a European specialty pharmaceutical company dedicated to acquiring, registering and marketing high medical value medicines throughout Europe, essentially for the hospital market. The SpePharm management team has a wealth of global experience within the pharmaceutical industry. In particular, the team has a well-established and in-depthknowledge of the European regulatory system, the hospital market, and niche and orphan products, with novel approaches and proven successes. | $28.5M / Aug 21, 2008 | |
|
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $12M / Series A / Sep 06, 2007 | |
|
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $19M / Series A / Mar 30, 2006 |
Co-Investors
About TVM Capital
TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.
TVM Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hubert Birner
General Partner
|
|||
Luc Marengere
Managing Partner
|
|||
|
Christoph Schröder
General Partner
|
|||
|
Friedrich Bornikoel
Managing Director
|
|||
Marc Riviere
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
FAQ
What does Hubert Birner invest in?
Hubert Birner invests primarily in Medical, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hubert Birner last invest?
The most recent investment recorded for Hubert Birner closed in Aug 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
